Potent inhibitor of VEGFR, PDGFR and FGFR
Cediranib is a highly potent and ATP-competitive inhibitor of VEGFR2 (IC50 = <1 nM). Cediranib also potently inhibits PDGFR1, VEGFR3, VEGFR1, c-Kit, PDGFR2 and FGFR1 (IC50 values are 2, 3, 5, 5, 26 and 36 nM, respectively), and inhibits CSF-1R, Src, and Abl (IC50 values are 110, 130 and 260 nM, respectively). Cediranib induces hypoxia, prevents VEGF-induced angiogenesis and suppresses homology-directed DNA repair (HDR) factors BRCA1/2 and RAD51. Cediranib decreases cell motility, proliferation and cell viability. Cediranib is active
in vivo
.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-125214 |
| Réf. fabricant | 18708156 |
| Nom chimique ou matériau | 4-[(4-Fluoro-2-methyl-1 H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline |
| CAS | 288383-20-0 |
| Quantité | 50 mg |
| Cible | VEGF Receptor Inhibitors |
| Formule moléculaire | C<sub>25</sub>H<sub>27</sub>FN<sub>4</sub>O<sub>3</sub> |
| Pureté | 0.98 |
